Immunome Statistics

Total Valuation

Immunome has a market cap or net worth of $684.71 million. The enterprise value is $447.30 million.

Market Cap	684.71M
Enterprise Value	447.30M

Important Dates

The last earnings date was Wednesday, November 13, 2024, after market close.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Immunome has 62.42 million shares outstanding. The number of shares has increased by 340.37% in one year.

Current Share Class	62.42M
Shares Outstanding	62.42M
Shares Change (YoY)	+340.37%
Shares Change (QoQ)	+0.45%
Owned by Insiders (%)	4.34%
Owned by Institutions (%)	73.64%
Float	45.24M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	58.08
Forward PS	n/a
PB Ratio	3.08
P/TBV Ratio	3.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	44.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.01.

Current Ratio	6.17
Quick Ratio	6.07
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -276.36% and return on invested capital (ROIC) is -62.32%.

Return on Equity (ROE)	-276.36%
Return on Assets (ROA)	-39.89%
Return on Capital (ROIC)	-62.32%
Revenue Per Employee	$184,164
Profits Per Employee	-$5.55M
Employee Count	55
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +34.93% in the last 52 weeks. The beta is 1.84, so Immunome's price volatility has been higher than the market average.

Beta (5Y)	1.84
52-Week Price Change	+34.93%
50-Day Moving Average	12.11
200-Day Moving Average	14.83
Relative Strength Index (RSI)	39.61
Average Volume (20 Days)	911,761

Short Selling Information

The latest short interest is 9.79 million, so 15.68% of the outstanding shares have been sold short.

Short Interest	9.79M
Short Previous Month	10.67M
Short % of Shares Out	15.68%
Short % of Float	21.63%
Short Ratio (days to cover)	10.77

Income Statement

In the last 12 months, Immunome had revenue of $10.13 million and -$305.35 million in losses. Loss per share was -$5.69.

Revenue	10.13M
Gross Profit	-81.00M
Operating Income	-111.71M
Pretax Income	-232.03M
Net Income	-305.35M
EBITDA	-110.44M
EBIT	-111.71M
Loss Per Share	-$5.69

Full Income Statement

Balance Sheet

The company has $240.13 million in cash and $2.72 million in debt, giving a net cash position of $237.41 million or $3.80 per share.

Cash & Cash Equivalents	240.13M
Total Debt	2.72M
Net Cash	237.41M
Net Cash Per Share	$3.80
Equity (Book Value)	214.91M
Book Value Per Share	3.56
Working Capital	204.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$86.19 million and capital expenditures -$52.48 million, giving a free cash flow of -$138.68 million.

Operating Cash Flow	-86.19M
Capital Expenditures	-52.48M
Free Cash Flow	-138.68M
FCF Per Share	-$2.22

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,102.86%
Pretax Margin	-3,014.59%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-340.37%
Shareholder Yield	-340.37%
Earnings Yield	-44.60%
FCF Yield	-20.25%

Analyst Forecast

The average price target for Immunome is $28.60, which is 160.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$28.60
Price Target Difference	160.71%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	70.89%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunome has an Altman Z-Score of 8.55 and a Piotroski F-Score of 2.

Altman Z-Score	8.55
Piotroski F-Score	2